# US 4,393,063 A · Treatment for gastric lesions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 4,393,063 A
- Document ID: US4393063A
- Status: Granted
- Kind: A
- Application number: 06/280,853
- Filed: 1981-07-06
- Granted: 1983-07-12
- Earliest claimed: 1977-08-23
- Assignees: Burroughs Wellcome Co.
- Inventors: Salvador E. Moncada
- Web page: https://patentgrep.com/patent/US4393063A

## CPC

- A61K 31/505: Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K 31/34: having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K 31/47: Quinolines; Isoquinolines
- A61K 31/52: Purines, e.g. adenine
- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K 31/557: Eicosanoids, e.g. leukotrienes {or prostaglandins}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Pharmaceutical combinations comprising (a) prostacyclin, dihydroprostacyclin or a pharmaceutically acceptable salt of either of these, and (b) a phosphodiesterase inhibitor. Pharmaceutical formulations comprising a combination as above and a pharmaceutically acceptable carrier. Methods are disclosed for preparing the combinations and the formulations. The combinations and formulations are useful for preventing or minimising platelet aggregation in blood, blood products or blood substitutes for example in the treatment of thrombosis, gastric lesions and wounds, and in the extra-corporeal circulation of blood and in blood separation processes.

## Claims

### Claim 1

A method for prophylaxis and/or treatment of a gastric lesion in a mammal, which comprises simultaneously or sequentially internally administering 1 part by weight of (a) a compound selected from the group consisting of prostacyclin, dihydroprostacyclin, and their pharmaceutically acceptable salts, in an amount insufficient to cause vasodilation, and 1 to 200 parts by weight of (b) a phosphodiesterase inhibitor selected from the group consisting of theophylline, 3-isobutyl-1-methyl xanthine, dipyridamole, a pharmaceutically acceptable salt of theophylline, a pharmaceutically acceptable salt of dipyridamole, and a pharmaceutically acceptable salt of 3-isobutyl-1-methyl xanthine.

### Claim 2

A method for the treatment of a gastric lesion in a mammal which comprises the internal administration of an effective gastric lesion treatment amount of 1 part by weight of sodium prostacyclin and 1 to 200 parts by weight of a phosphodiesterase inhibitor selected from the group consisting of theophylline, 3-isobutyl-1-methyl xanthine, dipyridamole, a pharmaceutically acceptable salt of theophylline, a pharmaceutically acceptable salt of dipyridamole, and a pharmaceutically acceptable salt of 3-isobutyl-1-methyl xanthine.

### Claim 3 (depends on 1)

The method of claim 1 in which the inhibitor is theophylline or a pharmaceutically acceptable salt thereof.

### Claim 4 (depends on 2)

The method of claim 2 in which the inhibitor is 3-isobutyl-1-methyl xanthine or a pharmaceutically acceptable salt thereof.